Minnar Christine M, Murphy William J
a Department of Dermatology , School of Medicine, University of California, Davis , Sacramento , CA , USA.
b Department of Internal Medicine , School of Medicine, University of California, Davis , Sacramento , CA , USA.
Hum Vaccin Immunother. 2016 Sep;12(9):2249-52. doi: 10.1080/21645515.2016.1174357. Epub 2016 Jul 13.
As the research and use of immunotherapies is expanding, isolating ideal combinational strategies has become the next goal for many investigators. Vaccine therapies are also becoming one of the many combinational strategies being utilized in conjunction with immunostimulatory antibodies such as checkpoint blockade or adjuvants to stimulate immune responses. Here we review aspects of the immune responses that remain to be considered for designing future targeted therapies given the recent findings of the role of out of order T cell activation signaling. Specifically, we review some considerations in generating primary T cell responses under conditions of strong immunostimulatory signals based on recent studies completed by our group and others.
随着免疫疗法的研究和应用不断扩展,分离出理想的联合策略已成为许多研究人员的下一个目标。疫苗疗法也正成为众多联合策略之一,这些策略与免疫刺激抗体(如检查点阻断剂或佐剂)联合使用,以刺激免疫反应。鉴于最近关于紊乱的T细胞激活信号作用的研究结果,本文将综述在设计未来靶向治疗时仍需考虑的免疫反应方面。具体而言,我们将根据我们团队及其他团队最近完成的研究,综述在强免疫刺激信号条件下产生初始T细胞反应时的一些注意事项。